From in vitro hepatic metabolic studies towards human health risk assessment: Two case studies of diuron and carbosulfan

Pesticide Biochemistry and Physiology

Volumn 107, Issue 2, 2013, Pages 258-265

  Abass, Khaled M ^a,b  

^a UNIVERSITY OF OULU   (Finland)

^b MENOUFIA UNIVERSITY   (Egypt)

Author keywords

In vitro metabolism; In vivo extrapolation; Pesticides; Risk assessment; Toxicokinetics

Indexed keywords

ANIMALIA;

EID: 84885373644     PISSN: 00483575     EISSN: 10959939     Source Type: Journal    
DOI: 10.1016/j.pestbp.2013.08.003     Document Type: Article

References (91)

1. Bigwood E.J. The acceptable daily intake of food additives. CRC Critic. Rev. Toxicol. 1973, 2:41-93.
2. Vettorazzi G. Safety factors and their application in the toxicological evaluation. The Evaluation of Toxicological Data for the Protection of Public Health Proceedings of the International Colloquium Luxembourg, December 1976 1977, 207-223. Pergamon Press, Oxford, UK. W.J. Hunter, J.G.P.M. Smeets (Eds.).
3. Renwick A.G. Safety factors and establishment of acceptable daily intakes. Food Addit. Contam. Part A. 1991, 8:135.
4. Renwick A.G. Data-derived safety factors for the evaluation of food additives and environmental contaminants. Food Addit. Contam. Part A. 1993, 10:275.
5. WHO/IPCS, Assessing human health risks of chemicals: derivation of guidance values for health-based exposure limits. Environmental health criteria, 170, World Health Organization, Geneva, 1994.
6. KEMI, Human health risk assessment. Proposals for the use of assessment (uncertainty) factors Application to risk assessment for plant protection products, industrial chemicals and biocidal products within the European Union, Swedish National Chemicals Inspectorate, Stockholm, Sweden, 2003.
7. WHO/IPCS, Chemical-specific adjustment factors for interspecies differences and human variability: guidance document for use of data in dose/concentration-response assessment. International Program on Chemical Safety, WHO/UNEP/ILO, World Health Organization, Geneva, 2005.
8. Dorne J.L., Renwick A.G. The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans. Toxicol. Sci. 2005, 86:20-26.
9. Walton K., Dorne J.L., Renwick A.G. Uncertainty factors for chemical risk assessment: interspecies differences in the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates. Food Chem. Toxicol. 2001, 39:667-680.
10. Walton K., Dorne J.L., Renwick A.G. Uncertainty factors for chemical risk assessment: interspecies differences in glucuronidation. Food Chem. Toxicol. 2001, 39:1175-1190.
11. Falk-Filipsson A., Hanberg A., Victorin K., Warholm M., Wallén M. Assessment factors - applications in health risk assessment of chemicals. Environ. Res. 2007, 104:108-127.
12. Dorne J.L., Walton K., Renwick A.G. Human variability in glucuronidation in relation to uncertainty factors for risk assessment. Food Chem. Toxicol. 2001, 39:1153-1173.
13. Dorne J.L., Walton K., Renwick A.G. Uncertainty factors for chemical risk assessment: human variability in the pharmacokinetics of CYP1A2 probe substrates. Food Chem. Toxicol. 2001, 39:681-696.
14. Dorne J.L., Walton K., Slob W., Renwick A.G. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?. Food Chem. Toxicol. 2002, 40:1633-1656.
15. Dorne J.L., Walton K., Renwick A.G. Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors. Food Chem. Toxicol. 2003, 41:225-245.
16. Dorne J.L., Walton K., Renwick A.G. Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food Chem. Toxicol. 2003, 41:201-224.
17. Dorne J.L., Walton K., Renwick A.G. Human variability for metabolic pathways with limited data (CYP2A6, CYP2C9, CYP2E1, ADH, esterases, glycine and sulphate conjugation). Food Chem. Toxicol. 2004, 42:397-421.
18. Dorne J.L., Walton K., Renwick A.G. Human variability in the renal elimination of foreign compounds and renal excretion-related uncertainty factors for risk assessment. Food Chem. Toxicol. 2004, 42:275-298.
19. Ginsberg G., Hattis D., Sonawane B., Russ A., Banati P., Kozlak M., Smolenski S., Goble R. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol. Sci. 2002, 66:185-200.
20. Hattis D., Erdreich L., Ballew M. Human variability in susceptibility to toxic chemicals - A preliminary analysis of pharmacokinetic data from normal volunteers. Risk Anal. 1987, 7:415-426.
21. Hattis D., Ginsberg G., Sonawane B., Smolenski S., Russ A., Kozlak M., Goble R. Differences in pharmacokinetics between children and adults - II Children's variability in drug elimination half-lives and in some parameters needed for physiologically-based pharmacokinetic modeling. Risk Anal. 2003, 23:117-142.
22. F. Kalberlah, K. Schneider, Quantification of extrapolation factors. Final report of the research project No 116 06 113 of the Federal Environmental Agency, Schriftenreihe der Bundesanstalt fur Arbeitsschutz und Arbeitsmedizin-Forschung-FB797, Germany, 1998.
23. Gundert-Remy U., Sonich-Mullin C. The use of toxicokinetic and toxicodynamic data in risk assessment: an international perspective. Sci. Total Environ. 2002, 288:3-11.
24. Brian Houston J. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 1994, 47:1469-1479.
25. Barter Z.E., Bayliss M.K., Beaune P.H., Boobis A.R., Carlile D.J., Edwards R.J., Houston J.B., Lake B.G., Lipscomb J.C., Pelkonen O.R., Tucke G.T., Rostami-Hodjegan A. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human micro-somal protein and hepatocellularity per gram of liver. Curr. Drug Metab. 2007, 8:33-45.
26. Johnson T.N., Tucker G.T., Tanner M.S., Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transplant. 2005, 11:1481-1493.
27. Pelkonen O., Turpeinen M. In vitro-in vivo extrapolation of hepatic clearance. Biological tools, scaling factors, model assumptions and correct concentrations. Xenobiotica 2007, 37:1066-1089.
28. Lin J.H., Lu A.Y.H. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. 1997, 49:403-449.
29. Pelkonen O., Raunio H. In vitro screening of drug metabolism during drug development: can we trust the predictions?. Expert Opin. Drug Metab. Toxicol. 2005, 1:49-59.
30. Pelkonen O., Turpeinen M., Uusitalo J., Rautio A., Raunio H. Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic Clin. Pharmacol. Toxicol. 2005, 96:167-175.
31. Skett P., Tyson C., Guillouzo A., Maier P. Report on the international workshop on the use of human in vitro liver preparations to study drug metabolism in drug development. Biochem. Pharmacol. 1995, 50:280-285.
32. Brandon E.F.A., Raap C.D., Meijerman I., Beijnen J.H., Schellens J.H.M. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol. Appl. Pharmacol. 2003, 189:233-246.
33. McGinnity D.F., Riley R.J. Predicting drug pharmacokinetics in humans from in vitro metabolism studies. Biochem. Soc. Trans. 2001, 29:135-139.
34. Pelkonen O., Kaltiala E.H., Larmi T.K.I., Karki N.T. Cytochrome P 450 linked monooxygenase system and drug induced spectral interactions in human liver microsomes. Chem. Biol. Interact. 1974, 9:205-216.
35. Fisher C.W., Shet M.S., Caudle D.L., Martin-Wixtrom C.A., Estabrook R.W. High-level expression in Escherichia coli of enzymatically active fusion proteins containing the domains of mammalian cytochromes P450 and NADPH-P450 reductase flavoprotein. Proc. Natl. Acad. Sci. USA 1992, 89:10817-10821.
36. 5. Eu. J. Biochem. 1992, 207:109-116.
37. Guengerich F.P. Cytochromes P450 of human liver. Classification and activity profiles of the major enzymes. Advances in Drug Metabolism in Man 1995, 179-231. Office for the Official Publications of the European Communities, Luxembourg. G.M. Pacifici, G.N. Fracchia (Eds.).
38. Asseffa A., Smith S.J., Nagata K., Gillette J., Gelboin H.V., Gonzalez F.J. Novel exogenous heme-dependent expression of mammalian cytochrome P450 using baculovirus. Arch. Biochem. Biophys. 1989, 274:481-490.
39. Gebhardt R., Hengstler J., Müller D., Glöckner R., Buenning P., Laube B., Schmelzer E., Ullrich M., Utesch D., Hewitt N., Ringel M., Hilz B., Bader A., Langsch A., Koose T., Burger H., Maas J., Oesch F. New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab. Rev. 2003, 35:145-213.
40. Carlile D.J., Hakooz N., Houston J.B. Kinetics of drug metabolism in rat liver slices: IV. Comparison of ethoxycoumarin clearance by liver slices, isolated hepatocytes, and hepatic microsomes from rats pretreated with known modifiers of cytochrome P-450 activity. Drug Metab. Dispos. 1999, 27:526-532.
41. Olinga P., Meijer D.K.F., Slooff M.J.H., Groothuis G.M.M. Liver slices in in vitro pharmacotoxicology with special reference to the use of human liver tissue. Toxicol. In Vitro. 1998, 12:77-100.
42. Worboys P.D., Bradbury A., Houston J.B. Kinetics of drug metabolism in rat liver slices. III. Relationship between metabolic clearance and slice uptake rate. Drug Metab. Dispos. 1997, 25:460-467.
43. Worboys P.D., Bradbury A., Houston J.B. Kinetics of drug metabolism in rat liver slices. II. Comparison of clearance by liver slices and freshly isolated hepatocytes. Drug Metab. Dispos. 1996, 24:676-681.
44. Ekins S., Ring B.J., Grace J., McRobie-Belle D.J., Wrighton S.A. Present and future in vitro approaches for drug metabolism. J. Pharmacol. Toxicol. Meth. 2000, 44:313-324.
45. Crommelin D.J.A., Sindelar R.D. Pharmaceutical Biotechnology an Introduction for Pharmacists and Pharmaceutical Scientists 1997, Harwood Academic, Australia, United Kingdom.
46. Aninat C., Piton A., Glaise D., Le Charpentier T., Langouet S., Morel F., Guguen-Guillouzo C., Guillouzo A. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab. Dispos. 2006, 34:75-83.
47. Anthérieu S., Chesné C., Li R., Camus S., Lahoz A., Picazo L., Turpeinen M., Tolonen A., Uusitalo J., Guguen-Guillouzo C., Guillouzo A. Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab. Dispos. 2010, 38:516-525.
48. Kanebratt K.P., Andersson T.B. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab. Dispos. 2008, 36:1444-1452.
49. Turpeinen M., Tolonen A., Chesne C., Guillouzo A., Uusitalo J., Pelkonen O. Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. Toxicol. In Vitro. 2009, 23:748-753.
50. Abass K., Lämsä V., Reponen P., Küblbeck J., Honkakoski P., Mattila S., Pelkonen O., Hakkola J. Characterization of human cytochrome P450 induction by pesticides. Toxicology 2012, 294:17-26.
51. Hodgson E., Rose R.L. Human metabolic interactions of environmental chemicals. J. Biochem. Mol. Toxicol. 2007, 21:182-186.
52. Eddershaw P.J., Dickins M. Advances in in vitro drug metabolism screening. Pharm. Sci. Technol. 1999, 2:13-19.
53. Tolonen A., Turpeinen M., Pelkonen O. Liquid chromatography-mass spectrometry in in vitro drug metabolite screening. Drug Discov. Today 2009, 14:120-133.
54. Riley R.J., McGinnity D.F., Austin R.P. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab. Dispos. 2005, 33:1304-1311.
55. Reponen P., Abass K., Mattila S., Pelkonen O. Overview of the metabolism and interactions of pesticides in hepatic in vitro systems. Int. J. Environ. Anal. Chem. 2010, 90:429.
56. D'Esposito F., Tattam B.N., Ramzan I., Murray M. A liquid chromatography/electrospray ionization mass spectrometry (LC-MS/MS) assay for the determination of irinotecan (CPT-11) and its two major metabolites in human liver microsomal incubations and human plasma samples. J. Chromatogr. B. 2008, 875:522-530.
57. Seiss M., Nitz S., Kleinsasser N., Buters J.T.M., Behrendt H., Hickel R., Reichl F.X. Identification of 2,3-epoxymethacrylic acid as an intermediate in the metabolism of dental materials in human liver microsomes. Dent 2007, 23:9-16.
58. Guengerich F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 1999, 39:1-17.
59. Guengerich F.P. Cytochromes P450 of human liver. Classification and activity profiles of the major enzymes. Advances in Drug Metabolism in Man 1995, 179-231. Office for the Official Publications of the European Communities, Luxembourg. G.M. Pacifici, G.N. Fracchia (Eds.).
60. White R.E. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu. Rev. Pharmacol. Toxicol. 2000, 40:133-157.
61. Rodrigues A.D. Integrated cytochrome P450 reaction phenotyping. Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem. Pharmacol. 1999, 57:465-480.
62. Rostami-Hodjegan A., Tucker G.T. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov. 2007, 6:140-148.
63. Beaune P.H., Kremers P.G., Kaminsky L.S., De Graeve J., Albert A., Guengerich F.P. Comparison of monooxygenase activities and cytochrome P-450 isozyme concentrations in human liver microsomes. Drug Metab. Dispos. 1986, 14:437-442.
64. Berthou F., Dreano Y., Belloc C., Kangas L., Gautier J., Beaune P. Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem. Pharmacol. 1994, 47:1883-1895.
65. Jacolot F., Simon I., Dreano Y., Beaune P., Riche C., Berthou F. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol. 1991, 41:1911-1919.
66. Wolkers J., Witkamp R.F., Nijmeijer S.M., Burkow I.C., de Groene E.M., Lydersen C., Dahle S., Monshouwer M. Phase I and phase II enzyme activities in Ringed seals (Phoca hispida): characterization of hepatic cytochrome P450 by activity patterns, inhibition studies, mRNA analyses, and western blotting. Aquatic Toxicol. 1998, 44:103-115.
67. Pelkonen O., Turpeinen M., Hakkola J., Honkakoski P., Hukkanen J., Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch. Toxicol. 2008, 82:667-715.
68. Bourrie M., Meunier V., Berger Y., Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. 1996, 277:321-332.
69. Clarke S.E., Ayrton A.D., Chenery R.J. Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica 1994, 24:517.
70. Nebert D.W., Russell D.W. Clinical importance of the cytochromes P450. Lancet 2002, 360:1155-1162.
71. Schmider J., Greenblatt D., von Moltke L., Harmatz J., Shader R. N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J. Pharmacol. Exp. Ther. 1995, 275:592-597.
72. Sesardic D., Boobis A.R., Murray B.P., Murray S., Segura J., de la Torre R., Davis D.S. Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man. Br. J. Clin. Pharmacol. 1990, 29:651-663.
73. Tolonen A., Petsalo A., Turpeinen M., Uusitalo J., Pelkonen O. In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies. J. Mass Spec. 2007, 42:960-966.
74. Turpeinen M., Uusitalo J., Jalonen J., Pelkonen O. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur. J. Pharm. Sci. 2005, 24:123-132.
75. Adler S., Basketter D., Creton S., Pelkonen O., van Benthem J., Zuang V., Andersen K., Angers-Loustau A., Aptula A., Bal-Price A., Benfenati E., Bernauer U., Bessems J., Bois F., Boobis A., Brandon E., Bremer S., Broschard T., Casati S., Coecke S., Corvi R., Cronin M., Daston G., Dekant W., Felter S., Grignard E., Gundert-Remy U., Heinonen T., Kimber I., Kleinjans J., Komulainen H., Kreiling R., Kreysa J., Leite S., Loizou G., Maxwell G., Mazzatorta P., Munn S., Pfuhler S., Phrakonkham P., Piersma A., Poth A., Prieto P., Repetto G., Rogiers V., Schoeters G., Schwarz M., Serafimova R., TÃhti H., Testai E., van Delft J., van Loveren H., Vinken M., Worth A., Zaldivar J. Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. Arch. Toxicol. 2011, 85:367-485.
76. Abass K., Reponen P., Mattila S., Pelkonen O. Metabolism of carbosulfan II. Human interindividual variability in its in vitro hepatic biotransformation and the identification of the cytochrome P450 isoforms involved. Chem. Biol. Interact. 2010, 185:163-173.
77. Abass K., Reponen P., Mattila S., Pelkonen O. Metabolism of carbosulfan. I. Species differences in the in vitro biotransformation by mammalian hepatic microsomes including human. Chem. Biol. Interact. 2009, 181:210-219.
78. Abass K., Reponen P., Turpeinen M., Jalonen J., Pelkonen O. Characterization of diuron N-demethylation by mammalian hepatic microsomes and cDNA-expressed human cytochrome P450 enzymes. Drug Metab. Dispos. 2007, 35:1634-1641.
79. Abass K., Reponen P., Jalonen J., Pelkonen O. In vitro metabolism and interaction of profenofos by human, mouse and rat liver preparations. Pestic. Biochem. Physiol. 2007, 87:238-247.
80. FAO/WHO, Pesticide residues in food - 2003. Report of the joint meeting of the FAO panel of experts on pesticide residues in food and the environment and the WHO core assessment group on pesticide residues, Geneva, Switzerland, 15-24 September 2003. Rome, World Health Organization and Food and Agriculture Organization of the United Nations (FAO Plant Production and Protection Paper, No. 176). 2003.
81. Marsden P.J., Kuwano E., Fukuto T.R. Metabolism of carbosulfan [2,3-dihydro-2,2-dimethylbenzofuran-7-yl (di-n-butylaminothio)methylcarbamate] in the rat and house fly. Pestic. Biochem. Physiol. 1982, 18:38-48.
82. Boxenbaum H. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance. Extrapolation of data to benzodiazepines and phenytoin. J. Pharmacokinet. Pharmacodyn. 1980, 8:165-176.
83. Calabrese E.J., Beck B.D., Chappell W.R. Does the animal-to-human uncertainty factor incorporate interspecies differences in surface area?. Regul. Toxicol. Pharm. 1992, 15:172-179.
84. Renwick A.G., Lazarus N.R. Human variability and noncancer risk assessment-an analysis of the default uncertainty factor. Regul. Toxicol. Pharm. 1998, 27:3-20.
85. FAO/WHO, Pesticide residues in food - 2002. Report of the joint meeting of the FAO panel of experts on pesticide residues in food and the environment and the WHO core assessment group on pesticide residues, Rome, Italy, 16-25 September 2002. Rome, World Health Organization and Food and Agriculture Organization of the United Nations. (2002).
86. FAO/WHO, Pesticide residues in food - 2005. Report of the joint meeting of the FAO panel of experts on pesticide residues in food and the environment and the WHO core assessment group on pesticide residues, Geneva, Switzerland, 20-29 September 2005. Rome, World Health Organization and Food and Agriculture Organization of the United Nations (FAO Plant Production and Protection Paper, No. 183). (2005).
87. FAO/WHO, Pesticide residues in food - 2004. Report of the joint meeting of the FAO panel of experts on pesticide residues in food and the environment and the WHO core assessment group on pesticide residues, Rome, Italy, 20-29 September 2004. Rome, World Health Organization and Food and Agriculture Organization of the United Nations (FAO Plant Production and Protection Paper, No. 178). (2005).
88. FAO/WHO, Pesticide residues in food, Report of the joint meeting of the FAO panel of experts on pesticide residues in food and the environment and the WHO core assessment group on pesticide residues, Rome, Italy, 9-18 September 2008. Rome, World Health Organization and Food and Agriculture Organization of the United Nations (FAO Plant Production and Protection Paper, No. 193). (2008).
89. Lin J.H., Lu A.Y.H. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 1998, 35.
90. Maenpaa J., Hall S.D., Ring B.J., Strom S.C., Wrighton S.A. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by [alpha]-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 1998, 8:137-156.
91. Yuan R., Parmelee T., Balian J.D., Uppoor R.S., Ajayi F., Burnett A., Lesko L.J., Marroum P. In vitro metabolic interaction studies: experience of the food and drug administration. Clin. Pharmacol. Ther. 1999, 66:9-15.